C1-Esterase Inhibitor
- TRADE NAMES: Berinert (CSL Behring); Cinryze (Viropharma)
- INDICATIONS: Hereditary angioedema type I and II
- CLASS: C1 inhibitor
- HALF-LIFE: 36.1 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
PREGNANCY CATEGORY: C
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric